CCO Annual Update
HIV/AIDS Annual Update 2009
The Virus, the Tissues and Immune Activation: What Makes HIV Infection Pathogenic? |
Module 1 of 8 |
|
Program Director: W. David Hardy, MD
- Daniel Douek, MD, MRCP, PhD
|
|
|
Daniel Douek, MD, MRCP, PhD, reviews deletion of gut-associated lymphoid tissue in early HIV-1 infection and the implications for progression of HIV-associated disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the depletion of CD4+ T cells in the gastrointestinal tract following HIV-1 infection
- Discuss immune activation following HIV-1 infection and its effects on the T-cell population in the gastrointestinal tract
- Explain how early HAART may have a greater effect on repopulating the CD4+ T-cell population in the gut than treatment during chronic infection
Abstract
|
New Insights Into Persistent Low-Level Viremia |
Module 2 of 8 |
|
Program Director: W. David Hardy, MD
- Robert F. Siliciano, MD, PhD
|
|
|
Robert F. Siliciano, MD, PhD, reviews the contribution of viral dynamics and the inhibitory mechanisms of antiretroviral agents to the persistence of low-level HIV-1 viremia during HAART and proposes a quantitative approach to selecting optimal HIV-1 treatment regimens.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the limitations of current methods for estimating the level of antiretroviral activity in HIV-1 treatment regimens, particularly in the setting of drug resistance
- Analyze evidence supporting the existence of multiple viral reservoirs with distinct decay kinetics in HIV-infected patients receiving HAART
- Discuss potential sources of persistent, low-level viremia in HIV-infected patients receiving HAART
- Illustrate the role of the dose-response curve slope in predicting the clinical efficacy of antiretroviral agents
Abstract
|
Timing and Choice of First-Line Antiretroviral Therapy |
Module 3 of 8 |
|
Program Chair: W. David Hardy, MD
|
|
Joel E. Gallant, MD, MPH, reviews optimal strategies for the initial treatment of HIV-1 infection in the context of updated guideline recommendations and recent clinical trials data.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the rationale for earlier vs later initiation of antiretroviral therapy
- Contrast the currently recommended first-line antiretroviral regimens
- Describe recommendations on treating special patient populations
- Interpret data on the use of newer agents in treatment-naive patients
Abstract
|
Inflammation and Non-AIDS Events: Are Antiretroviral-Treated Patients Aging Too Quickly and If So, Why? |
Module 4 of 8 |
|
Program Director: W. David Hardy, MD
|
|
Steven G. Deeks, MD, describes inflammation and immune activation related to HIV infection and how even though viral replication may be suppressed, HIV appears to mediate other disease states previously thought to be non-AIDS related.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the findings of studies regarding the relationships among HIV infection, antiretroviral therapy, and the development of non-AIDS events in HIV-infected patients
- Describe data that indicate differences in life expectancy between treated HIV-infected patients and those who are uninfected
- Summarize potential mechanisms for the interaction between HIV infection and development of non-AIDS events
|
Update on Managing Methamphetamine Abuse in the Setting of HIV Infection |
Module 5 of 8 |
|
Program Chair: Kimberly Y. Smith, MD, MPH
|
|
In this CME-certified module, Steven Shoptaw, PhD, offers practical management strategies for treating methamphetamine use in HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current epidemiology of methamphetamine abuse in HIV-infected patients
- Detail the common effects of methamphetamine in HIV-infected individuals
- Associate behaviors related to methamphetamine use with HIV-related transmission risk
- Describe clinically relevant drug-drug interactions between methamphetamine and antiretrovirals
- Identify practical interventions that can be used in HIV care settings to address methamphetamine use and addiction
Abstract
|
State-of-the-Art Management of Sexually Transmitted Diseases |
Module 6 of 8 |
|
Program Director: Kimberly Y. Smith, MD, MPH
|
|
Jeanne Marrazzo, MD, reviews current management strategies of sexually transmitted diseases in HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe recent trends in the incidence of syphilis in HIV-infected patients
- Explain the interpretation of serologic tests for syphilis, including treponemal enzyme immunoassays, in the HIV-infected patient
- List therapeutic options for management of Neisseria gonorrhoeae, including options for patients intolerant of cephalosporins
- Discuss the relationship between herpes simplex virus type 2 infection and HIV transmission
- Name at least 2 other sexually transmitted diseases for which HIV providers should consider testing
Abstract
|
Biomedical Approaches to Prevention |
Module 7 of 8 |
|
Program Director: Joseph J. Eron, Jr., MD
|
|
Sharon L. Hillier, PhD, outlines the successes and failures of clinical trials of HIV prevention and describes current clinical trials of microbicides and antiretroviral therapy for pre-exposure prophylaxis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the results of completed studies of nonspecific microbicides for prevention of HIV
- Discuss the preclinical and animal model data supporting the use of antiretrovirals for HIV prevention
- Cite studies of oral and topical tenofovir or tenofovir/emtricitabine that will assess their activity in reducing HIV infections
- Summarize the additional bridging studies that will be needed before oral or topical pre-exposure prophylaxis can be operationalized
Abstract
|
Experiences as an HIV Provider in Africa |
Module 8 of 8 |
|
Program Director: Joseph J. Eron, Jr., MD
|
|
Charles Steinberg, MD, reviews data and personal experience about providing healthcare in the resource-poor nation Uganda in Africa.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss prevalence of HIV among countries in Africa
- Describe regimens commonly use for first-line antiretroviral therapy in Africa
- Recount common opportunistic infections seen among patients in Africa and their therapy in HIV-coinfected patients
- Explain HIV prevention efforts in Africa
- Summarize societal issues surrounding women that may affect rates of transmission of HIV to them or their partners
Abstract
|
HIV/AIDS Annual Update 2009 Book
 |
This comprehensive reference outlines the most important recent clinical and research advances in the field. Topics include pathogenesis, antiretroviral therapy, sexually transmitted diseases, biomedical prevention, methamphetamine use, and treatment in resource-limited settings. |
|
 |
Download AU Book |
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|